Citigroup Maintains Buy on SpyGlass Pharma, Raises Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $45.
Last updated: 2026-11-19 07:29:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
SpyGlass Pharma, Inc. (SGP) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $29.62, with a market capitalization of $1.05B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.06 to $39.92. This page covers its latest market performance, valuation, price trends and company information.
$1.05B | |
$31.44 | |
$32.26 | |
$29.43 | |
$31.44 | |
85.11K | |
114.18K | |
-- | |
$39.92 | |
$17.06 | |
-- | |
2026-09-30 |
SpyGlass Pharma, Inc. (SGP) last closed at $29.62 as of 2026-11-18 21:57:00, down 4.31% ($1.36) from the previous close of $31.44.
During the latest regular trading session, SGP traded between $29.43 and $32.26, with a volume of 85.11K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, SpyGlass Pharma, Inc. (SGP) moved from $34.18 to $29.62, representing a decline of 13.34% ($4.56).
The stock traded between $29.10 and $38.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 99.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 54.9%
SGP is currently trading at $29.62, placing it 54.9% of the way from its 52-week low of $17.06 to its 52-week high of $39.92. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for SpyGlass Pharma, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Oct 22, 2009 |
| Payment Date | Nov 30, 2009 |
| Dividend Per Share | $0.065 |
Latest news related to SpyGlass Pharma, Inc. and SGP stock.
Citigroup analyst Yigal Nochomovitz maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $45.
Stifel analyst Tom Stephan maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $42 to $44.
HC Wainwright & Co. analyst Yi Chen maintains SpyGlass Pharma (NASDAQ:SGP) with a Buy and raises the price target from $37 to $43.
Eligible investors can buy real shares of SpyGlass Pharma, Inc. (SGP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to SGP, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between SGP shares and USD.
SGP Shares to USD
1.00 SGP shares = 29.619 USD
Calculations are estimates based on the latest available price and are for reference only.